Which has the lower trailing P/E, MANH or MEDP?

MEDP has the lower trailing P/E: MANH trades at 57.83 and MEDP at 34.42. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, MANH or MEDP?

Over the past five years, MEDP grew revenue faster — MANH at a 12.69% CAGR versus MEDP at 22.03%.

Is MANH or MEDP more profitable?

MANH runs the higher net margin — MANH at 18.67% versus MEDP at 17.67%.

How have MANH and MEDP total returns compared?

Over the past 10 years, MANH delivered 13.30% and MEDP delivered 34.74% annualized total return. Past performance doesn't predict future results.

Manhattan Associates, Inc. (MANH) vs Medpace Holdings, Inc. (MEDP)

A side-by-side comparison of Manhattan Associates, Inc. and Medpace Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 11, 2026. Differences are shown without an overall score or investment verdict.

Different business models: MANH is classified in Technology; MEDP is classified in Healthcare. Margin, capital intensity, and valuation differences should be interpreted in that sector context.

MANH

Manhattan Associates, Inc.

$11.77B

$201.82TechnologyDelayed quote: Sep 11, 2026, 4:00 PM EDT

MEDP

Medpace Holdings, Inc.

$16.40B

$587.52HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT

Total return — MANH vs MEDP

growth of $100 · dividends reinvested · last 10y

MANH +233.0% (+12.8%/yr)MEDP +1860.2% (+34.7%/yr)MEDP compounded faster over this window

Log scale — wide-divergence pair

MANH MEDP

MANH vs MEDP: by the numbers

•MEDP is the larger company ($16.40B vs $11.77B market cap).
•MEDP trades at the lower trailing earnings multiple (34.42 vs 57.83 P/E), one valuation lens rather than an overall verdict.
•MANH converts more revenue to profit (18.67% vs 17.67% net margin).
•MEDP grew revenue faster over the past five years (22.03% vs 12.69% CAGR).

Metrics side by side

Valuation

Metric	MANH	MEDP
P/E ratio	57.83	34.42
Forward P/E	36.71	33.38
P/S ratio	10.45	5.89
P/B ratio	74.71	37.80
EV / EBITDA	41.45	26.20
FCF yield	3.39%	4.28%

Profitability

Metric	MANH	MEDP
Gross margin	54.65%	28.76%
Operating margin	24.33%	20.97%
Net margin	18.67%	17.67%
ROE	133.48%	113.29%
ROIC	90.92%	77.00%

Growth (annualized)

Metric	MANH	MEDP
Revenue CAGR (5Y)	12.69%	22.03%
EPS CAGR (5Y)	21.59%	30.90%
FCF CAGR (5Y)	19.51%	23.40%
Total return CAGR (5Y)	4.78%	24.92%

Frequently asked

Which has the lower trailing P/E, MANH or MEDP?: MEDP has the lower trailing P/E: MANH trades at 57.83 and MEDP at 34.42. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, MANH or MEDP?: Over the past five years, MEDP grew revenue faster — MANH at a 12.69% CAGR versus MEDP at 22.03%.
Is MANH or MEDP more profitable?: MANH runs the higher net margin — MANH at 18.67% versus MEDP at 17.67%.
How have MANH and MEDP total returns compared?: Over the past 10 years, MANH delivered 13.30% and MEDP delivered 34.74% annualized total return. Past performance doesn't predict future results.

Go deeper

Full MANH analysis Full MEDP analysis Interactive comparison tool

Dig into the metrics

Manhattan Associates P/E ratio Medpace P/E ratio Manhattan Associates ROE Medpace ROE Manhattan Associates operating margin Medpace operating margin Manhattan Associates revenue growth Medpace revenue growth Manhattan Associates free cash flow Medpace free cash flow

Manhattan Associates & Medpace appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 11, 2026.